Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future...

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• Novel targeted drugs are increasingly used in cancer therapy.
• Combinations of targeted drugs with radiotherapy are currently limited.
• Cetuximab is the only approved targeted drug for combined use with radiotherapy in head and neck cancer.

Purpose of the Study:

• To review the current status and future outlook of targeted drug and radiotherapy combinations for solid tumors.
• To provide a radio-oncological perspective on advanced targeted combined treatment concepts.

Main Methods:

• Literature review of targeted therapies and their combination with radiotherapy.
• Focus on anti-EGFR and anti-angiogenic targeted agents.
• Analysis of clinical development stages for promising compounds.

Main Results:

• Several targeted compounds, including trastuzumab, panitumumab, erlotinib, cilengitide, and bevacizumab, are in advanced clinical development.
• These agents, targeting EGFR or angiogenesis, are considered promising for combination therapies.
• The landscape of targeted drug-radiotherapy combinations is evolving rapidly.

Conclusions:

• Targeted drug-radiotherapy combinations represent a significant area of development in oncology.
• Further research and clinical trials are needed to establish the efficacy and safety of these combinations.
• The integration of targeted therapies with radiotherapy holds potential for improved solid tumor treatment outcomes.